Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pitavastatin - Kowa

Next Previous
Drug Profile

Pitavastatin - Kowa

Alternative Names: Alipza; Itavastatin; Livalo; Livazo; Nisvastatin; NK 104; NK-104-CR; NK-104-LH; NK-104-PH; NKS 104; P 872441; Pitavastatin Calcium; Redevant; Trolise; Vezepra

Latest Information Update: 11 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nissan Chemical Industries; ViiV Healthcare
  • Developer AbbVie; Algorithm; Daiichi Sankyo Company; Eli Lilly and Company; ESTEVE; JW Pharmaceutical; Kowa; Nissan Chemical Industries; Recordati; Tanabe Pharma Corporation
  • Class Alcohols; Alkenes; Antihyperlipidaemics; Carboxylic acids; Cyclopropanes; Fluorobenzenes; Quinolines; Skin disorder therapies; Small molecules
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia
  • Registered Hyperlipoproteinaemia type IIa
  • Phase III Cardiovascular disorders
  • Discontinued Alzheimer's disease

Most Recent Events

  • 01 Dec 2025 Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation
  • 02 Dec 2024 Pitavastatin is still in phase III trials for Cardiovascular disorders in Zimbabwe, Uganda, Thailand, Spain, South Africa, Puerto Rico, Peru, India, Haiti, Canada, Brazil, Botswana, USA (PO) (NCT02344290)
  • 19 Nov 2024 Discontinued - Phase-III for Hypercholesterolaemia (Combination therapy) in South Korea (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top